Naftidrofuryl

Naftidrofuryl
Clinical data
Trade names	Praxilene
AHFS/Drugs.com	International Drug Names
Routes of; administration	Oral
ATC code	C04AX21 (WHO) ;
Legal status
Legal status	UK: POM (Prescription only);
Pharmacokinetic data
Metabolism	Hepatic
Elimination half-life	1 - 3.5 hours
Identifiers
	IUPAC name (RS)-2-(diethylamino)ethyl 3-(1-naphthyl)-2-(tetrahydrofuran-2-ylmethyl)propanoate;
CAS Number	31329-57-4 ;
PubChem CID	4417;
ChemSpider	4264 ;
UNII	42H8PQ0NMJ;
ChEMBL	ChEMBL1620794;
CompTox Dashboard (EPA)	DTXSID3023344 ;
ECHA InfoCard	100.045.960
Chemical and physical data
Formula	C24H33NO3
Molar mass	383.532 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(OCCN(CC)CC)C(Cc2c1ccccc1ccc2)CC3OCCC3;
	InChI InChI=1S/C24H33NO3/c1-3-25(4-2)14-16-28-24(26)21(18-22-12-8-15-27-22)17-20-11-7-10-19-9-5-6-13-23(19)20/h5-7,9-11,13,21-22H,3-4,8,12,14-18H2,1-2H3 ; Key:KBAFPSLPKGSANY-UHFFFAOYSA-N ;
	(verify)

Naftidrofuryl (INN), also known as nafronyl or as the oxalate salt naftidrofuryl oxalate or nafronyl oxalate, is a vasodilator used in the management of peripheral and cerebral vascular disorders. It is also claimed to enhance cellular oxidative capacity. The drug act as a selective antagonist of 5-HT₂ receptors (with action as an inverse agonist of the 5-HT_2A receptor specifically characterized).^[1]^[2]^[3] Naftidrofuryl is also licensed for the treatment of intermittent claudication due to peripheral arterial disease.

Naftidrofuryl is marketed under a variety of trade names, including Artocoron, Azunaftil, Di-Actane, Dusodril, Enelbin, Frilix, Gevatran, Iridus, Iridux, Luctor, Nafti, Naftilong, Naftodril, Nafoxal, Praxilene, Sodipryl retard, and Vascuprax.

Historically, it has been used to treat sudden idiopathic hearing loss and acute tinnitus.^[4]

Naftidrofuryl may be effective for relieving the pain of muscle cramps.^[5]

Adverse Effects

Naftidrofuryl has been associated with nausea, abdominal pain and rash. Rarely, hepatitis and liver failure have been reported.^[6]

References

^ Lanzer P, Topol EJ (20 December 2013). Pan Vascular Medicine: Integrated Clinical Management. Springer. pp. 1394–. ISBN 978-3-642-56225-9.
^ Morton IK, Hall JM (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 147–. ISBN 978-94-011-4439-1.
^ Aly SA, Hossain M, Bhuiyan MA, Nakamura T, Nagatomo T (August 2009). "Assessment of binding affinity to 5-hydroxytryptamine 2A (5-HT2A) receptor and inverse agonist activity of naftidrofuryl: comparison with those of sarpogrelate". Journal of Pharmacological Sciences. 110 (4): 445–50. doi:10.1254/jphs.09124FP. PMID 19672037.
^ "DER ARZNEIMITTELBRIEF: Infusionstherapie beim idiopathischen Hörsturz? Dextran Dextran Hörsturz Hydroxyethylstärke Pentoxifyllin Pentoxifyllin Procain Taprosten". www.der-arzneimittelbrief.de.
^ Katzberg HD, Khan AH, So YT (February 2010). "Assessment: symptomatic treatment for muscle cramps (an evidence-based review): report of the therapeutics and technology assessment subcommittee of the American academy of neurology". Neurology. 74 (8): 691–6. doi:10.1212/WNL.0b013e3181d0ccca. PMID 20177124.
^ Brayfield A, ed. (14 January 2014). "Naftidrofuryl Oxalate". Martindale: The Complete Drug Reference. Pharmaceutical Press. Retrieved 6 August 2014.

This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.

[LanzerTopol2013-1] Lanzer P, Topol EJ (20 December 2013). Pan Vascular Medicine: Integrated Clinical Management. Springer. pp. 1394–. ISBN 978-3-642-56225-9.

[MortonHall2012-2] Morton IK, Hall JM (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 147–. ISBN 978-94-011-4439-1.

[AlyHossain2009-3] Aly SA, Hossain M, Bhuiyan MA, Nakamura T, Nagatomo T (August 2009). "Assessment of binding affinity to 5-hydroxytryptamine 2A (5-HT2A) receptor and inverse agonist activity of naftidrofuryl: comparison with those of sarpogrelate". Journal of Pharmacological Sciences. 110 (4): 445–50. doi:10.1254/jphs.09124FP. PMID 19672037.

[4] "DER ARZNEIMITTELBRIEF: Infusionstherapie beim idiopathischen Hörsturz? Dextran Dextran Hörsturz Hydroxyethylstärke Pentoxifyllin Pentoxifyllin Procain Taprosten". www.der-arzneimittelbrief.de.

[Katzberg-5] Katzberg HD, Khan AH, So YT (February 2010). "Assessment: symptomatic treatment for muscle cramps (an evidence-based review): report of the therapeutics and technology assessment subcommittee of the American academy of neurology". Neurology. 74 (8): 691–6. doi:10.1212/WNL.0b013e3181d0ccca. PMID 20177124.

[MD-6] Brayfield A, ed. (14 January 2014). "Naftidrofuryl Oxalate". Martindale: The Complete Drug Reference. Pharmaceutical Press. Retrieved 6 August 2014.

[1]

[2]

[3]

[4]

[5]

[6]

v t e Peripheral vasodilators (C04)
Phenylethanolamine derivatives	Isoxsuprine Buphenine Bamethan
Alpha blockers	Non-selective Buflomedil Phentolamine Phenoxybenzamine Tolazoline Selective α₁-blockers Alfuzosin Doxazosin Prazosin Silodosin Tamsulosin Terazosin
Niacin and derivatives	Niacin Nicotinyl alcohol Inositol nicotinate Ciclonicate
Purine derivatives	Pentifylline Xantinol nicotinate Pentoxifylline Etofylline nicotinate
Ergot alkaloids	Ergoloid Nicergoline Dihydroergocristine
Other peripheral vasodilators	Cyclandelate Vincamine Moxisylyte Bencyclane Vinburnine Sulcotidil Naftidrofuryl Butalamine Visnadine Cetiedil Cinepazide Ifenprodil Azapetine Fasudil

Naftidrofuryl

Adverse Effects

See also

References